Post Profile






Alnylam ends development of drug due to patient deaths in trial

(Reuters) - Shares of Alnylam Pharmaceuticals Inc fell sharply on Wednesday after the company halted development of an experimental therapy for a rare genetic condition when a late-stage study showed that patients given the drug were more likely to die than patients treated with a placebo.
read more

share

Related Posts


Alvine Pharmaceuticals Reports Positive Results With ALV003 In Phase 1 Trial Of Therapy In Development For Celiac Disease

Health : Medical News Today

Alvine Pharmaceuticals, Inc., today announced proof of concept in a Phase 1 Trial of ALV003, an oral protease therapy in development to detoxify gluten, intended for use by patients with celiac disease. The trial results confirmed t...

Kite immunotherapy drug helps blood cancer patients in study

Health : Reuters: Health

(Reuters) - Kite Pharma Inc on Monday said its experimental CAR T-cell therapy, which helps the immune system fight cancer, was highly effective in treating aggressive non-Hodgkin lymphoma, although two deaths were related to the dr...

Regeneron's Eylea combination therapy fails mid-stage study

Health : Reuters: Health

(Reuters) - Regeneron Pharmaceuticals Inc said a combination therapy containing its flagship eye drug, Eylea, was inferior to Eylea alone in a mid-stage trial involving patients with wet age-related macular degeneration (AMD), a lea...

A biotech company erased $3 billion in value overnight after one of its drugs failed a key trial (ALNY)

Business & Finance : Business Insider: Clusterstock

Biotech company Alnylam Pharmaceuticals is down almost 50% Thursday after stopping a late-stage clinical trial. The drug, revusiran, was being developed to treat a condition called hereditary ATTR amyloidosis with cardiomyopathy. It...

Safety data support human testing of hematopoietic stem cell gene therapy for mucopolysaccharid I

Health : EurekAlert: Health

(Mary Ann Liebert, Inc./Genetic Engineering News) Extensive biosafety studies of hematopoietic stem cell (HSC) gene therapy, intended to replace a protein that patients with the inherited disease mucopolysaccaridosis I (MPS I) canno...

Comments


Copyright © 2016 Regator, LLC